How big is BioNexus Gene Lab Corp.?

As of Jun 18, BioNexus Gene Lab Corp. has a market capitalization of 5.17 million and reported net sales of 9.26 million with a net profit of -2.12 million over the last four quarters.

Market Cap: As of Jun 18, BioNexus Gene Lab Corp. has a market capitalization of 5.17 million, classified as a Micro Cap.<BR><BR>Recent Quarterly Performance: For the latest four quarters, the company reported net sales of 9.26 million and a net profit of -2.12 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the shareholder's funds amounted to 8.32 million, while total assets were reported at 10.43 million.

What does BioNexus Gene Lab Corp. do?

BioNexus Gene Lab Corp. is a micro-cap company in the miscellaneous industry, reporting net sales of $2 million and a net loss of $1 million for Q1 2025. Key metrics include a market cap of $5.17 million, a debt equity ratio of -0.46, and a return on equity of -27.32%.

Overview: <BR>BioNexus Gene Lab Corp. operates in the miscellaneous industry and is classified as a micro-cap company.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 2 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -1 Million (Quarterly Results - Mar 2025) <BR>Market-cap: USD 5.17 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.46 <BR>Return on Equity: -27.32% <BR>Price to Book: 0.67<BR><BR>Contact Details: <BR>Registrar Address: Not available.

Should I buy, sell or hold BioNexus Gene Lab Corp.?

Is BioNexus Gene Lab Corp. overvalued or undervalued?

As of December 9, 2022, BioNexus Gene Lab Corp. is considered overvalued and risky due to negative valuation ratios, poor performance metrics, and a significant decline in long-term returns despite strong short-term gains.

As of 9 December 2022, the valuation grade for BioNexus Gene Lab Corp. moved from expensive to risky, indicating a shift in perception regarding its financial health. The company appears to be overvalued, given its negative valuation ratios and poor performance metrics. Key ratios include a Price to Book Value of 0.72, an EV to Sales ratio of 0.22, and a ROCE of -54.21%, all suggesting significant financial distress.<BR><BR>In comparison to peers, BioNexus Gene Lab Corp. has a less favorable EV to EBITDA of -0.95 compared to CervoMed, Inc. at -2.3987 and Team, Inc. at 9.7974, highlighting its weaker operational efficiency. Additionally, while the company has shown strong short-term returns, with a YTD return of 103.79% compared to the S&P 500's 12.22%, its long-term performance is concerning, with a 3Y return of -95.94% versus the S&P 500's 70.41%. This stark contrast reinforces the notion that the stock is currently overvalued.

Is BioNexus Gene Lab Corp. technically bullish or bearish?

As of September 5, 2025, BioNexus Gene Lab Corp. is in a mildly bullish trend, supported by positive indicators like a bullish MACD and Bollinger Bands, with a year-to-date return of 103.79% compared to the S&P 500's 12.22%.

As of 5 September 2025, the technical trend for BioNexus Gene Lab Corp. has changed from bullish to mildly bullish. The current stance is mildly bullish, supported by a bullish MACD on the weekly timeframe, bullish Bollinger Bands on both weekly and monthly timeframes, and a bullish On-Balance Volume (OBV) on both timeframes. The Dow Theory also indicates a mildly bullish position on both weekly and monthly charts. <BR><BR>In terms of performance, the stock has shown significant returns, with a year-to-date return of 103.79% compared to the S&P 500's 12.22%, and a one-year return of 36.01% versus the S&P 500's 17.14%.